15 Background: Paracetamol exposure has been positively associated with asthma development. The relative importance of prenatal vs infant exposure and confounding by indication remains elusive. We examined the association of prenatal and infant (first 6 months) paracetamol exposure with asthma development while addressing confounding by indication. Methods: We used information from the Norwegian Mother and Child Cohort Study, 20 including 53169 children for evaluation of current asthma at 3 years, 25394 for current asthma at 7 years and 45607 for dispensed asthma medications at 7 years in the Norwegian Prescription Database. We calculated adjusted relative risks (adj. RR) and 95% confidence intervals (CI) using log-binomial regression.
Introduction
Asthma is the most common chronic disease during childhood. 1, 2 Prenatal and infant paracetamol exposures are proposed to be positively associated with asthma. 3-5 5 However, few previous studies were able to evaluate the relative importance of prenatal vs infant paracetamol exposure. [6] [7] [8] Paracetamol is the recommended analgesic/antipyretic for pregnant women and infants. 9 If the observed associations reflect true underlying effects, this is a public 10 health concern. A limited number of previous studies of prenatal paracetamol exposure and asthma development considered confounding by indication. 7, 10, 11 An inherent limitation in observational studies is the possibility of unmeasured confounding. One approach to 15 examine whether associations in observational studies might reflect unmeasured characteristics influencing the propensity for exposure is to use negative controls. 12, 13 Examples of negative controls include maternal use of paracetamol outside pregnancy and the father's use of 20 paracetamol. If the associations are similar for maternal paracetamol use outside pregnancy and paternal paracetamol use, it is likely that confounding by genetic or shared environmental characteristics is present. 12, 13 The objective of the study was thus to examine the asso- 25 ciation of prenatal and infant paracetamol exposure with asthma development while addressing confounding by indication. To further assess whether the previously reported associations reflected unmeasured confounding, we evaluated maternal paracetamol use outside pregnancy and pa- 30 ternal paracetamol use. Since ibuprofen is used for many of the same indications as paracetamol, we also evaluated the association between prenatal ibuprofen exposure and asthma development.
Methods 35 
Study population
We used data from the Norwegian Mother and Child Cohort Study (MoBa) conducted by the Norwegian Institute of Public Health. 14, 15 MoBa recruited pregnant women between 1999 and 2008, at approximately 18 40 weeks of gestation. The participation rate of invited pregnant women was 40.6%. Mothers could participate with more than one pregnancy, resulting in approximately 95 200 mothers and 114500 children. All participants gave written informed consent. In May 2014, the 114761 chil- 45 dren participating in MoBa were linked to the Medical Birth Registry of Norway (henceforth called 'birth registry') and the Norwegian Prescription Database (henceforth called 'prescription registry'). Children not linked to the birth registry (n ¼ 499) and children from multiple births (n ¼ 50 3,971) were not eligible for the current study. We used information from the MoBa questionnaires completed at 18 and 30 gestational weeks and when the child was 6 months, 3 years and 7 years old. The Norwegian Data Inspectorate and the Regional Ethics Committee for Medical Research of 55 South/East Norway approved this study.
Exposures
Participating mothers reported the use of medications for different indications during pregnancy through questionnaires completed at 18 gestational weeks, 30 gestational 60 weeks and when the child was 6 months old. The mother was asked if she had experienced the disease/symptom of interest, and to list the medications she had used for that specific disease/symptom. The mother also listed the child's use of medications during the first 6 months of life.
Outcomes
We examined two asthma outcomes based on the MoBa questionnaires and one outcome based on dispensed asthma medications. (i) We defined current asthma at 3 5 years as a 'yes' in response to current asthma in combination with use of short-or long-acting beta2-agonists (R03AC) and/or inhaled corticosteroids (R03BA) in the past year reported in the 3-year questionnaire. (ii) Current asthma at 7 years was defined according to three positive 10 criteria reported in the 7-year questionnaire: a positive report of ever asthma, experiencing asthma symptoms during the past year and using medications for asthma in the past year. (iii) A separate asthma definition at age 7 was based on information from the prescription registry. A child was 15 regarded as having asthma if he/she had a dispensed asthma medication during the past year in addition to a second dispensed prescription within 1 year after the first. Asthma medications included R03AC, R03BA, R03AK and R03DC. 20 
Other variables
Maternal characteristics included age, parity, education, pre-pregnancy body mass index (weight in kilograms divided by measured height in metres squared), smoking during pregnancy, asthma, respiratory tract infections/ 25 influenza during pregnancy, pain during pregnancy, fever during pregnancy and use of antibiotics during pregnancy. Child characteristics included the child's gender, birthweight, breastfeeding in the first 6 months, respiratory tract infections in the first 6 months, body mass index at 6 30 months and use of antibiotics during the first 6 months. We classified antibiotics for systemic use based on ATC codes J01A-J01X.
Statistical analyses
The analysis consisted of several steps. First, we examined 35 the associations between prenatal and infant paracetamol exposure with asthma development using log-linear regression, reporting relative risks (RR) and 95% confidence intervals (CI). The multivariable analyses adjusted for all the potential confounding factors as in Table 1 . We used 40 cluster variance estimation to account for siblings in the analyses. In order to evaluate whether maternal history of asthma was an effect modifier on the multiplicative scale, we included product terms in the multivariable regression models. 45 Second, we evaluated the likelihood of confounding by indication by focusing on three common indications for use of paracetamol in pregnancy: pain, fever and respiratory tract infections/influenza. There was little a priori evidence that maternal pain during pregnancy might be 50 associated with asthma development in the offspring. However, we wanted to evaluate whether maternal use of paracetamol for different/partly unrelated indications yielded similar associations with asthma development in the offspring. We categorized mutually exclusive exposure 55 categories of mothers who had experienced the different indications with and without the use of paracetamol. In order to evaluate whether these maternal indications acted as effect modifiers on the multiplicative scale, we included product terms in the multivariable regression 60 models.
Third, we conducted sensitivity analyses to explore unmeasured confounding by background factors influencing the propensity for paracetamol exposure by examining maternal use of paracetamol the past 6 months before preg-65 nancy, maternal use of paracetamol during the first 6 months after pregnancy and the father's paracetamol use.
Fourth, since paracetamol and ibuprofen are used for similar indications, information about maternal use of ibuprofen during pregnancy was extracted (M01AE01). We 70 subsequently evaluated prenatal exposure to paracetamol and ibuprofen in combination (neither, only ibuprofen, only paracetamol, both ibuprofen and paracetamol), to evaluate whether maternal use of these two medications during pregnancy yielded the same association with 75 asthma development.
There were approximately 10-15% of observations with missing information in the multivariable analyses. We therefore conducted multiple imputation by chained equations, imputing a total of 20 datasets. 80 All of the P-values presented are two-sided. We conducted the analyses using Stata version 13 (Statacorp, TX).
Results
A total of 53169 children were included in the analysis of 85 current asthma at 3 years, 25394 in the evaluation of current asthma at 7 years and 45607 in the evaluation of dispensed asthma medications at 7 years ( Figure 1 ). The characteristics among individuals with and without the necessary follow-up information are given in Supplementary 90 Table 1 (available as Supplementary data at IJE online). A total of 27.9% of children were only exposed to paracetamol during pregnancy, 15.5% only during infancy and 19.1% were exposed both during pregnancy and infancy. The distribution of characteristics by prenatal and infant 95 paracetamol exposure is given in Table 1 .
A total 5.7% of children had current asthma at 3 years, 5.1% had current asthma at 7 years and 4.8% had dispensed asthma medications at 7 years. There were independent associations between asthma at 3 years with prenatal paracetamol exposure (adj. RR 1.13; 95% CI: 1.02-1.25) and use of paracetamol during infancy (adj. RR 1.29; 5 95% CI: 1.16-1.45) ( Table 2) . Similar results were observed for current asthma at 7 years and dispensed asthma medications at 7 years (Table 2 ). There was no strong evidence of multiplicative interaction between prenatal and infant paracetamol exposure 10 on asthma development (P-values interaction > 0.07).
Separate analyses of prenatal and infant paracetamol exposure with asthma development are included in Supplementary Table 2 (available as Supplementary data at IJE online). The results indicated a slightly stronger as- 15 sociation between children exposed to paracetamol during two time periods of pregnancy with asthma development (Supplementary Table 2 ). Our findings indicated evidence of an interaction by maternal history of asthma on the association between 20 infant paracetamol exposure and asthma at 3 years (P-value interaction < 0.01) ( Supplementary Table 3 , available as Supplementary data at IJE online). However, there was no strong evidence of an interaction by maternal history of asthma for the association between prenatal paracetamol 25 and asthma development, or the association between infant paracetamol exposure and the asthma outcomes at 7 years (P-values interaction > 0.1) ( Supplementary Table 3 ).
We evaluated respiratory tract infections/influenza, fever and pain during pregnancy as common indications 30 for using paracetamol. Prenatal paracetamol exposure for these three indications yielded similar associations with asthma development (Table 3 ). Furthermore, pain showed a positive association with asthma development without the use of paracetamol (Table 3 ). The strongest 35 association was seen if the mother used paracetamol during pregnancy for more than one indication, adj. RR 1.94 (95% CI: 1.58-2.37) for current asthma at 3 years (Table  3) . In order to further evaluate the potential role of confounding by indication, we conducted stratified analyses 40 of the association between prenatal paracetamol exposure and asthma development by the three indications in turn (Supplementary Table 4 , available as Supplementary data at IJE online). The results indicated no strong evidence of multiplicative interaction (P-values interaction > 0.3). 45 Likewise, we also conducted a stratified analysis of the association between infant paracetamol exposure and asthma development by the child's experience of respiratory tract infections during the first 6 months of life (Supplementary Table 5 , available as Supplementary data 50 at IJE online). The results indicated no evidence of multiplicative interaction (P-values interaction > 0.5).
There was no strong evidence of an association between paternal paracetamol use and asthma in the offspring (Supplementary Table 6 , available as Supplementary data at IJE online). Likewise, maternal paracetamol use during the past 6 months before pregnancy, or the first 6 months after delivery, showed no strong evidence of an association with asthma in the offspring ( Supplementary Table 6 ). 5 Prenatal exposure to ibuprofen was only reported for 5.8% of children. Prenatal exposure to ibuprofen only (no exposure to paracetamol) showed some evidence of an association with current asthma at 3 years, adj. RR 1.31 (95% CI: 1.00, 1.72), whereas there was weak 10 evidence for a positive association with current asthma at 7 years and dispensed asthma medications at 7 years ( Table 4 ).
The results from the multiple imputation analyses were similar to the complete case analyses (Supplementary 15 
Discussion
This large-scale prospective observational study indicated that both prenatal and infant paracetamol exposure showed independent positive associations with asthma de- 25 velopment. Furthermore, the association between prenatal paracetamol exposure and asthma development was similar if used for respiratory tract infections/influenza, fever or pain. Prenatal ibuprofen exposure was only associated with an early asthma phenotype. 30 
Comparison with previous studies
Our finding that prenatal and infant paracetamol exposures are positively associated with asthma development is largely in accordance with results summarized in metaanalyses. 3-5 However, most studies in these meta-analyses did not address confounding by indication.
Of the three previous studies examining prenatal para-5 cetamol exposure and asthma development that adjusted for infections/antibiotics during pregnancy, all reported a positive association. 7, 10, 11 The magnitude of the associations in these studies ranged between 1.15 and 1.29. 7, 10, 11 Among previous studies of infant paracetamol exposure and 10 asthma development that adjusted for the child's experience of respiratory tract infections, 6, 8, [16] [17] [18] [19] three studies reported a positive association. 6, 16, 19 These studies reported that paracetamol exposure during infancy was associated with a doubling in the risk of asthma development. 6, 16, 19 15 However, one of these studies indicated that the association was restricted to girls. 6 Our study is the first to evaluate the relative importance of prenatal vs infant paracetamol exposure and able to account for common indications during both exposure periods. This allowed us to show that both 20 prenatal and infant paracetamol exposures had independent positive associations with asthma development after adjustment for confounding by indication during both exposure periods.
Two previous studies examined prenatal ibuprofen 25 exposure and asthma development. 8, 11 One of these studies examined both prenatal and infant ibuprofen exposure, reporting a positive association with infant ibuprofen exposure, adjusted odds ratio 1.20 (95% confidence interval 1.02-1.40), but no strong evidence of 30 an association with prenatal ibuprofen exposure, 1.17 (0.78-1.76). 8 Our results indicated weak evidence for a positive association between prenatal ibuprofen exposure with asthma at 3 years and no strong evidence for an association with asthma at 7 years. We could not evaluate 35 infant ibuprofen exposure as too few were exposed (0.1%).
Interpretation of main findings
Pregnant women who have asthma might be more likely to choose paracetamol as an analgesic/antipyretic compared 40 with acetylsalicylic acid and other non-steroidal antiinflammatory drugs, due to sensitization. 20 However, our results provided no strong evidence of an effect modification of maternal history of asthma on the observed associations. Pain during pregnancy included maternal report of pelvic prolapse, back pain, neck/shoulder pain, migraine/head ache, fibromyalgia and/or unspecified muscle pain.
Infant paracetamol exposure reflects the child's use of paracetamol the first 6 months of life.
The results presented are based on a complete case analysis. A total of 47 173 children were included in the multivariable analysis of current asthma at 36 months, 22 102 children in the analysis of current asthma at 7 years and 38 677 in the analysis of dispensed asthma medications at 7 years. a Associations adjusted for maternal age, parity, education, pre-pregnancy body-mass index, smoking during pregnancy, asthma, respiratory tract infections/influenza during pregnancy, fever during pregnancy, pain during pregnancy and antibiotic use during pregnancy, in addition to the child's gender, birth weight, breastfeeding the first 6 months of life, respiratory tract infections by 6 months, body mass index at 6 months and use of antibiotics by 6 months. This is the first study to address maternal conditions in pregnancy with and without the use of paracetamol in relation to asthma in the offspring. Maternal paracetamol use for respiratory tract infections/influenza, fever or pain 5 all showed a positive association with asthma in the offspring, wheras maternal report of pain was the only indication that was positively associated with asthma in the offspring if the mother did not use paracetamol. Pain is highly subjective and likely influenced by a number of fac- 10 tors, and these findings therefore need to be replicated and explored in depth. One might speculate that maternal pain during pregnancy is a potential source of stress. A possible explanation for our finding is therefore the association between prenatal exposure to stress and asthma de- 15 velopment. [21] [22] [23] [24] However, our observed associations of prenatal and infant paracetamol exposure with asthma development might also reflect the severity of the condition leading to paracetamol use. It was not possible to further evaluate this using the information 20 available. RTI/influenza during pregnancy included maternal report of upper respiratory tract infections (ear, throat, sinus infections and/or colds) lower respiratory tract infections (pneumonia and/or bronchitis) and/or influenza. Pain during pregnancy included maternal report of pelvic prolapse, back pain, neck/shoulder pain, migraine/head ache, fibromyalgia and/or unspecified muscle pain. This analysis excluded individuals who used paracetamol for other/unspecified reason. This included 7528 children in the evaluation of current asthma at 3 years, 3484 children in the evaluation of current asthma at 7 years and 6450 children in the evaluation of dispensed asthma medications at 7 years. The results presented are based on a complete case analysis. A total of 43 789 children were included in the multivariable analysis of current asthma at 36 months, 20 800 children in the analysis of current asthma at 7 years and 37 783 in the analysis of dispensed asthma medications at 7 years. RTI, respiratory tract infections. a Associations adjusted for maternal age, parity, education, pre-pregnancy body mass index, smoking during pregnancy, asthma and antibiotic use during pregnancy b
The group who reported fever or use of paracetamol for fever were allowed to also report RTI/influenza or use of paracetamol for RTI/influenza. All other categories are mutually exclusive.
We cannot exclude the possibility that the association of prenatal and infant paracetamol exposures with asthma development might be partly mediated by later paracetamol exposure. 5 The evaluation of maternal paracetamol use outside pregnancy and paternal paracetamol use was motivated by a negative controls approach. 12, 13 Evaluation of these negative controls allowed an assessment of the likelihood of unmeasured confounding by characteristics that might 10 influence the propensity for using paracetamol. Only one study has previously evaluated maternal paracetamol use after pregnancy and paternal paracetamol use. 25 In line with the findings from this previous study, we found no strong evidence for an association between maternal para-15 cetamol use outside pregnancy or paternal paracetamol use with asthma in the offspring, supporting the conclusion that the results were not caused by underlying characteristics or health behaviour. If the observed association between paracetamol expos-20 ure and asthma development reflects a true effect, proposed biological mechanisms include the ability of paracetamol to induce oxidative stress and enhance Th2 cell polarization and mediation of non-eosinophilic inflammatory responses. 26, 27 Increased oxidative stress during 25 pregnancy and infancy is hypothesized to increase the risk of asthma. 28 This hypothesis is also supported by studies reporting an inverse association between maternal antioxidant intake during pregnancy and asthma in the offspring. 29, 30 Results from the Avon Longitudinal Study 30 of Parents and Children also indicate that maternal antioxidant gene polymorphism may modify the association between prenatal paracetamol exposure and asthma development. 7 Ibuprofen is used for many of the same indications as 35 paracetamol. According to Norwegian guidelines, ibuprofen is not recommended for pregnant women or infants who weigh less than 10 kg. 9 Based on our results, we could not conclude with certainty that prenatal ibuprofen exposure did not have a similar positive association with asthma 40 development as observed for prenatal paracetamol exposure, since we likely had limited power to detect an association with our outcomes at 7 years. Ibuprofen is a COX-1 inhibitor, contributing to an up-regulation of leukotrienes, thought to play a role in asthma pathogenesis. 31
45

Strengths and limitations
Strengths of the current study include the size, detailed evaluation of different indications for prenatal paracetamol exposure and evaluation of prenatal ibuprofen exposure, in addition to the evaluation of maternal paracetamol 50 use outside pregnancy and paternal paracetamol use as negative controls. This is the first study comparing the association between prenatal exposure with different indications, and use of paracetamol for different indications with development of asthma. It is also the first study examining The results presented are based on a complete case analysis. A total of 51 011 children were included in the multivariable analysis of current asthma at 36 months, 24 114 children in the analysis of current asthma at 7 years and 44 009 in the analysis of dispensed asthma medications at 7 years. a Associations adjusted for maternal age, parity, education, pre-pregnancy body mass index, smoking during pregnancy, asthma, respiratory tract infections/influenza during pregnancy, pain during pregnancy, fever during pregnancy and antibiotic use during pregnancy.
the relative importance of prenatal vs infant paracetamol exposure in relation to asthma development, that was able to adjust for confounding by indication during both exposure periods. 5 The main limitation of the information available in MoBa was the ability to account for the amount of paracetamol used and severity of the underlying indications. However, by evaluating prenatal paracetamol exposure for more than one indication and during more than one time 10 period of pregnancy, we evaluated two approaches to distinguish between amounts of exposure. The classification of prenatal and infant paracetamol exposures through questionnaires could have resulted in misclassification. Due to the prospective data collection, any misclassifica- 15 tion of paracetamol exposure is unlikely to be differential by the child's asthma status. Another limitation is that the information available for the child's use of medications during the first 6 months of life did not include which specific condition the medications had been used for. By using 20 maternal report of the child's asthma status, there may also be misclassification of the outcome. However, maternal report that the child used asthma medications in the past year on the 7-years questionnaire in MoBa compared well with dispensed asthma medications in the prescription 25 registry. 32 A comparison of MoBa participants against all Norwegian women who gave birth during the inclusion period indicated that several high-risk groups might be under-represented. 15 This might influence the generalizability of our results. [33] [34] [35] Our study further required infor- 30 mation from a number of follow-up questionnaires. A comparison of eligible individuals with and without the necessary follow-up information indicated that mothers of children with the necessary follow-up information were older, were more likely to have higher education and were 35 less likely to smoke (Supplementary Table 1 ). We further evaluated bias due to loss to follow-up, by using dispensed asthma medications as an additional outcome which showed associations similar to those of the questionnairebased outcome.
Conclusion
Our study is by far the largest study to provide evidence that prenatal and infant paracetamol exposures have independent positive associations with asthma development. Our findings suggest that the associations could not be 45 fully explained by confounding by indication. Paracetamol is the most commonly used analgesic/antipyretic among pregnant women and infants, and uncovering potential adverse effects is of public health importance. Based on the inherent challenges in observational studies, evidence from 50 a randomized controlled trial would be beneficial.
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